MedTrace Logo

EXPLorative Data Collection for Patient chAracterIzation, treatmeNt Pathways and Outcomes of IRON Preparations

NCT03382275 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 51

Last updated 2019-07-02

No results posted yet for this study

Summary

By describing the characteristics of iron deficiency (ID) patients treated with various oral or intravenous iron formulations and their outcomes, this registry will provide the medical community with important information to support treatment decisions for their patients regarding data on effectiveness, safety, tolerability, treatment persistence, quality of life, and therapeutic costs. This will ultimately support improvements to patient care, including the long-term outcomes of patients with ID.

Conditions

  • Iron-deficiency

Interventions

DRUG

Iron Supplement

any oral or intravenous prescription iron supplement

Sponsors & Collaborators

  • Shield Therapeutics

    collaborator INDUSTRY

  • GWT-TUD GmbH

    lead OTHER

Principal Investigators

  • David Pittrow, MD, PhD · GWT-TUD GmbH

  • Stefan Schreiber, MD, PhD · Klinik für Innere Medizin I, Universitätsklinikum Kiel

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-01-16
Primary Completion
2019-04-20
Completion
2019-04-20

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03382275 on ClinicalTrials.gov